某药业的未来发展分析之绿金变黄金的秘密PPT课件.pptxVIP

;台灣生技製藥業的展望;Definition of each section;Is Continued Reliance On Blockbuster Drugs Enough?;Sensitivity to Changing Key Variables in Pipeline Model;藥物開發程序;專業藥廠的經營模式_3 models;Rationality of R/D Market; Dilemma – Taiwan pharma Industry ;情境推演;Trend of Taiwan Pharma–Industry; Limitation of Pharma–Industry;The Trend of Taiwan Pharmaceutical Taiwan Market Trend;Top 100-200 generic companies can survive in China China will become the fifth-largest pharmaceutical market with the estimated revenues of over USD24 billion by 2010. (3X of current size) (source: BCG group) Multinational companies can fill these needs and survive Lots of generic companies with competitive advantages or unique capabilities can survive Focusing the head of Chinese operations on assessing and shaping local abilities are essential Some specialty Pharma companies with competitive advantages or unique capabilities can survive Only Taiwanese can do successful business in China market Building the abilities to support Chinese operation with world-class regulatory specialists and marketers can win;Taiwanese Pharma is in a difficult position for RD ;Positioning;Position of TTY Center Lab ;專業藥廠的經營模式_3 models;Strength of Center Lab;Conclusions for TTY’s Business;台灣東洋於1996年組織重整與再造; Position of Company Type;TTY Marketing Business Models; Value Chain Positioning;Effects of Core Product;Definition of Product Category; Category Management; Role Territory;Definition of each section;;台灣藥廠的命運;Imagination; Part III: Portfolio Analysis;;Vision: Global specialty pharma company ;台灣藥廠的命運;;What is Nutritherapy?;OTC;Semi-OTC/ Nutritherapy;Pure OTC;何謂Nutritheropy (營養療法);;TTY Marketing Business Models;Definition of each section;全球市場趨勢